Xzid 80mg Tablet contains Gliclazide, a sulfonylurea class oral hypoglycemic agent used in the management of type 2 diabetes mellitus. It functions primarily by stimulating pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Xzid is indicated for patients with non-insulin-dependent diabetes mellitus who have not achieved adequate glycemic control through diet and exercise alone. The 80mg dosage provides an effective option for improving glycemic regulation and minimizing the risk of long-term diabetic complications such as neuropathy, retinopathy, and nephropathy. Gliclazide exhibits a selective action on pancreatic receptors, which contributes to a lower risk of hypoglycemia compared to other sulfonylureas. It is typically administered orally once or twice daily with meals to enhance absorption and reduce gastrointestinal discomfort. Patients should be monitored regularly for blood glucose levels, renal and hepatic function, and signs of hypoglycemia. Caution is advised in patients with impaired liver or kidney function, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Lifestyle modifications including diet and exercise should be maintained during treatment with Xzid 80mg Tablet to optimize therapeutic outcomes.